董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Benjamin L. Palleiko | 男 | Chairman of the Board and Director | 60 | 未披露 | 11.72 | 2026-09-24 |
| R. Scott Struthers | 男 | Director | 64 | 未披露 | 3.00 | 2026-09-24 |
| William C. Fairey, Jr. | 男 | Director | 62 | 未披露 | 3.00 | 2026-09-24 |
| Albert Cha | 男 | Chief Executive Officer and Director | 53 | 未披露 | 198.37 | 2026-09-24 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Fran Adams | 男 | Chief Financial Officer | 45 | 未披露 | 1.41 | 2026-09-24 |
| Ali Jackson | 女 | General Counsel | 36 | 未披露 | 未持股 | 2026-09-24 |
| Kevin Li | 男 | Chief Business Officer | 34 | 未披露 | 未持股 | 2026-09-24 |
| Albert Cha | 男 | Chief Executive Officer and Director | 53 | 未披露 | 198.37 | 2026-09-24 |
董事简历
中英对照 | 中文 | 英文- Benjamin L. Palleiko
-
BenjaminL.Palleiko于2016年8月加入Kalvista Limited担任首席财务官，并于2016年11月被任命为我们的首席财务官。Palleiko先生于2019年3月被任命为我们的首席商务官，并担任首席财务官。在加入我们之前，Palleiko先生于2012年至2016年6月担任Cielo Therapeutics，Inc.的联合创始人兼首席执行官。他之前是Ore Pharmaceutical Holdings Inc.和Penwest Pharmaceuticals Co.的高级副总裁和首席财务官。在他的职业生涯早期，Palleiko先生是Robertson Stephens和SunTrust Bank的投资银行家。Palleiko先生在塔夫茨大学（Tufts University）获得数量经济学学士学位，并在芝加哥大学（University of Chicago）获得金融学工商管理硕士学位和国际关系硕士学位。他曾在美国海军（U.S.Navy）担任海军飞行员。
Benjamin L. Palleiko,has served as KalVista Pharmaceuticals, Inc. Chief Executive Officer and as a member of KalVista Pharmaceuticals, Inc. Board since March 2024. Mr. Palleiko joined Kalvista Pharmaceuticals, Inc. as Chief Financial Officer in August 2016, was appointed to the additional role of Chief Business Officer in March 2019, and promoted to President in January 2023. His prior roles include Senior Vice President and Chief Financial Officer of Ore Pharmaceutical Holdings Inc. and Penwest Pharmaceuticals Co. Earlier in his career Mr. Palleiko spent a decade as an investment banker at firms including Robertson Stephens. Mr. Palleiko holds a B.A. in Quantitative Economics from Tufts University and an M.B.A. in Finance and M.A. in International Relations from the University of Chicago. Prior to his business career, he served as a Naval Aviator in the U.S. Navy. - BenjaminL.Palleiko于2016年8月加入Kalvista Limited担任首席财务官，并于2016年11月被任命为我们的首席财务官。Palleiko先生于2019年3月被任命为我们的首席商务官，并担任首席财务官。在加入我们之前，Palleiko先生于2012年至2016年6月担任Cielo Therapeutics，Inc.的联合创始人兼首席执行官。他之前是Ore Pharmaceutical Holdings Inc.和Penwest Pharmaceuticals Co.的高级副总裁和首席财务官。在他的职业生涯早期，Palleiko先生是Robertson Stephens和SunTrust Bank的投资银行家。Palleiko先生在塔夫茨大学（Tufts University）获得数量经济学学士学位，并在芝加哥大学（University of Chicago）获得金融学工商管理硕士学位和国际关系硕士学位。他曾在美国海军（U.S.Navy）担任海军飞行员。
- Benjamin L. Palleiko,has served as KalVista Pharmaceuticals, Inc. Chief Executive Officer and as a member of KalVista Pharmaceuticals, Inc. Board since March 2024. Mr. Palleiko joined Kalvista Pharmaceuticals, Inc. as Chief Financial Officer in August 2016, was appointed to the additional role of Chief Business Officer in March 2019, and promoted to President in January 2023. His prior roles include Senior Vice President and Chief Financial Officer of Ore Pharmaceutical Holdings Inc. and Penwest Pharmaceuticals Co. Earlier in his career Mr. Palleiko spent a decade as an investment banker at firms including Robertson Stephens. Mr. Palleiko holds a B.A. in Quantitative Economics from Tufts University and an M.B.A. in Finance and M.A. in International Relations from the University of Chicago. Prior to his business career, he served as a Naval Aviator in the U.S. Navy.
- R. Scott Struthers
-
R.Scott Struthers是我们的联合创始人，自2008年11月以来一直担任我们的董事会成员，并自2008年12月以来担任我们的总裁兼首席执行官。任职Crinetics公司之前，他曾担任NeurocrineBiosciences，Inc.公司的高级董事兼内分泌和新陈代谢主管（1998年至2008年）。在Neurocrine，他发起并领导公司致力于发现和开发口服活性的非肽类GNRH拮抗剂，包括Elagolix。任职Neurocrine公司之前，他曾共同创立Sciencemedia公司（从1995年到1998年），以开发生命科学和高等教育市场的电子学习解决方案，并领导Biosym Technologies公司的合同研究工作（从1992年到1995年），以开发和应用药物发现的计算工具。Struthers博士还是圣地亚哥企业家交易所（San Diego Entrepreneurs Exchange）的联合创始人，该公司是一家非营利组织，他自2009年1月起担任其董事。
R. Scott Struthers,is co-founder and has served on board of directors since November 2008 and as President and Chief Executive Officer since December 2008. Prior to Crinetics, he was senior director and head of endocrinology and metabolism at Neurocrine Biosciences, Inc., from 1998 to 2008. At Neurocrine, he initiated and led the company's efforts to discover and develop orally active, nonpeptide GnRH antagonists, including elagolix. Prior to Neurocrine, from 1995 to 1998, he co-founded ScienceMedia Inc. to develop eLearning solutions for the life sciences and higher education markets and led contract research efforts at Biosym Technologies, from 1992 to 1995, to develop and apply computational tools for drug discovery. In 2009, Dr. Struthers co-founded the San Diego Entrepreneurs Exchange, a nonprofit organization which he has served on the board of directors of since January 2009. Since October 2021, Dr. Struthers has served as chairperson of the board of Radionetics Oncology, a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for oncology indications in which Crinetics holds a minority equity stake. He holds a Ph.D. in physiology and pharmacology from the University of California, San Diego based on the work he performed at the Salk Institute for Biological Studies. Dr. Struthers' knowledge of business, as well as his extensive development and clinical experience, contributed to board of directors' conclusion that he should serve as a director of company. - R.Scott Struthers是我们的联合创始人，自2008年11月以来一直担任我们的董事会成员，并自2008年12月以来担任我们的总裁兼首席执行官。任职Crinetics公司之前，他曾担任NeurocrineBiosciences，Inc.公司的高级董事兼内分泌和新陈代谢主管（1998年至2008年）。在Neurocrine，他发起并领导公司致力于发现和开发口服活性的非肽类GNRH拮抗剂，包括Elagolix。任职Neurocrine公司之前，他曾共同创立Sciencemedia公司（从1995年到1998年），以开发生命科学和高等教育市场的电子学习解决方案，并领导Biosym Technologies公司的合同研究工作（从1992年到1995年），以开发和应用药物发现的计算工具。Struthers博士还是圣地亚哥企业家交易所（San Diego Entrepreneurs Exchange）的联合创始人，该公司是一家非营利组织，他自2009年1月起担任其董事。
- R. Scott Struthers,is co-founder and has served on board of directors since November 2008 and as President and Chief Executive Officer since December 2008. Prior to Crinetics, he was senior director and head of endocrinology and metabolism at Neurocrine Biosciences, Inc., from 1998 to 2008. At Neurocrine, he initiated and led the company's efforts to discover and develop orally active, nonpeptide GnRH antagonists, including elagolix. Prior to Neurocrine, from 1995 to 1998, he co-founded ScienceMedia Inc. to develop eLearning solutions for the life sciences and higher education markets and led contract research efforts at Biosym Technologies, from 1992 to 1995, to develop and apply computational tools for drug discovery. In 2009, Dr. Struthers co-founded the San Diego Entrepreneurs Exchange, a nonprofit organization which he has served on the board of directors of since January 2009. Since October 2021, Dr. Struthers has served as chairperson of the board of Radionetics Oncology, a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for oncology indications in which Crinetics holds a minority equity stake. He holds a Ph.D. in physiology and pharmacology from the University of California, San Diego based on the work he performed at the Salk Institute for Biological Studies. Dr. Struthers' knowledge of business, as well as his extensive development and clinical experience, contributed to board of directors' conclusion that he should serve as a director of company.
- William C. Fairey, Jr.
-
暂无中文简介
William C. Fairey, Jr. has served as an independent director on Frazier Life Sciences Acquisition Corp. Ii's board of directors since September 2026. Mr. Fairey served as Executive Vice President and Chief Commercial Officer of MyoKardia, Inc. ("MyoKardia"), a public clinical stage biopharmaceutical company, from 2019 to 2020 prior to its acquisition by Bristol Myers Squibb Company in 2020. Prior to MyoKardia, from 2018 to 2019, Mr. Fairey served as Executive Vice President and Chief Operating Officer of ChemoCentryx, Inc. ("ChemoCentryx"), a publicly traded biopharmaceutical company acquired by Amgen Inc. in 2022. Prior to ChemoCentryx, Mr. Fairey served in various roles at Actelion Pharmaceuticals Ltd., a pharmaceutical company, from 2001 until it was acquired by Johnson & Johnson in 2017. Mr. Fairey currently serves on the board of directors of Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a publicly traded rare and orphan disease company, where he has served since August 2021, Ascendis Pharma A/S (Nasdaq: ASND), a publicly traded biotechnology company, where he has served since 2022, and Rein Therapeutics, Inc. (Nasdaq: RNTX), a publicly traded clinical stage biopharmaceutical company, where he has served since 2023. Previously, he served on the board of KalVista, a publicly traded rare disease company, from 2024 until 2026. Mr. Fairey holds a B.S. in biology from the University of Oregon and an M.B.A. from Saint Mary's College of California. -
暂无中文简介
- William C. Fairey, Jr. has served as an independent director on Frazier Life Sciences Acquisition Corp. Ii's board of directors since September 2026. Mr. Fairey served as Executive Vice President and Chief Commercial Officer of MyoKardia, Inc. ("MyoKardia"), a public clinical stage biopharmaceutical company, from 2019 to 2020 prior to its acquisition by Bristol Myers Squibb Company in 2020. Prior to MyoKardia, from 2018 to 2019, Mr. Fairey served as Executive Vice President and Chief Operating Officer of ChemoCentryx, Inc. ("ChemoCentryx"), a publicly traded biopharmaceutical company acquired by Amgen Inc. in 2022. Prior to ChemoCentryx, Mr. Fairey served in various roles at Actelion Pharmaceuticals Ltd., a pharmaceutical company, from 2001 until it was acquired by Johnson & Johnson in 2017. Mr. Fairey currently serves on the board of directors of Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a publicly traded rare and orphan disease company, where he has served since August 2021, Ascendis Pharma A/S (Nasdaq: ASND), a publicly traded biotechnology company, where he has served since 2022, and Rein Therapeutics, Inc. (Nasdaq: RNTX), a publicly traded clinical stage biopharmaceutical company, where he has served since 2023. Previously, he served on the board of KalVista, a publicly traded rare disease company, from 2024 until 2026. Mr. Fairey holds a B.S. in biology from the University of Oregon and an M.B.A. from Saint Mary's College of California.
- Albert Cha
-
自2016年Carbylan Therapeutics，Inc.交易完成以来，Albert Cha一直担任我们的董事会成员。Cha博士从2007年11月开始担任Carbylan董事会成员。他于2000年9月加入Vivo Capital公司（梦百合投资公司），在那里他曾担任多种职务。Cha博士目前担任Ascendis PharmaA/s和几家私营生物技术和医疗设备公司的董事会成员。在过去的五年中，他还担任过生物医药控股有限公司、AclarisTherapeutics，Inc.、SierraOncology，Inc.（前身为Pronai Therapeutics，Inc.和AirxPanders，Inc.）的董事会成员。Cha博士获得斯坦福大学（Stanford University）的B.S.和M.S.以及加州大学洛杉矶分校（University of California at Los Angeles）的M.D.和博士学位。
Albert Cha has served as a member of board of directors since November 2014 and as the Chairman of board of directors since May 2021. Dr. Cha is a Managing Partner with Frazier Life Sciences. He previoly was a managing partner at Vivo Capital LLC, a healthcare investment firm, where he has served in vario positions, most recently as a managing partner. Dr. Cha previoly served as a member of the board of directors of KalVista Pharmaceuticals, Inc., Aclaris Therapeutics, a publicly traded dermatology company, Sierra Oncology, Inc., a publicly traded oncology company, Biohaven Pharmaceutical Holding Company Ltd, a publicly traded clinical stage biopharmaceutical company targeting neurological diseases and Menlo Therapeutics, Inc., a publicly traded late stage biopharmaceutical company focused on the treatment of prurit. Dr. Cha holds a B.S. and an M.S. from Stanford University and an M.D. and a Ph.D. from the University of California at Los Angeles. - 自2016年Carbylan Therapeutics，Inc.交易完成以来，Albert Cha一直担任我们的董事会成员。Cha博士从2007年11月开始担任Carbylan董事会成员。他于2000年9月加入Vivo Capital公司（梦百合投资公司），在那里他曾担任多种职务。Cha博士目前担任Ascendis PharmaA/s和几家私营生物技术和医疗设备公司的董事会成员。在过去的五年中，他还担任过生物医药控股有限公司、AclarisTherapeutics，Inc.、SierraOncology，Inc.（前身为Pronai Therapeutics，Inc.和AirxPanders，Inc.）的董事会成员。Cha博士获得斯坦福大学（Stanford University）的B.S.和M.S.以及加州大学洛杉矶分校（University of California at Los Angeles）的M.D.和博士学位。
- Albert Cha has served as a member of board of directors since November 2014 and as the Chairman of board of directors since May 2021. Dr. Cha is a Managing Partner with Frazier Life Sciences. He previoly was a managing partner at Vivo Capital LLC, a healthcare investment firm, where he has served in vario positions, most recently as a managing partner. Dr. Cha previoly served as a member of the board of directors of KalVista Pharmaceuticals, Inc., Aclaris Therapeutics, a publicly traded dermatology company, Sierra Oncology, Inc., a publicly traded oncology company, Biohaven Pharmaceutical Holding Company Ltd, a publicly traded clinical stage biopharmaceutical company targeting neurological diseases and Menlo Therapeutics, Inc., a publicly traded late stage biopharmaceutical company focused on the treatment of prurit. Dr. Cha holds a B.S. and an M.S. from Stanford University and an M.D. and a Ph.D. from the University of California at Los Angeles.
高管简历
中英对照 | 中文 | 英文- Fran Adams
Fran Adams自2026年4月起担任Research Alliance Corporation IV的首席财务官。Adams先生目前是van den Boom and Associates的合伙人，拥有超过20年的会计和财务经验。Adams先生在多家私营生命科学公司担任零碎首席财务官以及财务和会计主管。在加入van den Boom and Associates之前，他曾在多家上市公司工作，专注于财务报告和技术会计。Adams先生还曾担任Research Alliance Corporation III自2026年2月成立以来的首席财务官。Adams博士拥有圣地亚哥州立大学会计专业的工商管理学士学位，是一名活跃的加州注册会计师。
Fran Adams has been Research Alliance Corporation Iv's Chief Financial Officer since April 2026. Mr. Adams is currently a Partner at van den Boom and Associates with over 20 years of accounting and finance experience. Mr. Adams serves as the fractional chief financial officer and head of finance and accounting at various private life sciences companies. Prior to joining van den Boom and Associates worked at multiple public companies focusing on financial reporting and technical accounting. Mr. Adams has also served as Chief Financial Officer of Research Alliance Corporation III since its inception in February 2026. Dr Adams holds a bachelor's degree in Business Administration with emphasis in accounting from San Diego State University and is an active California CPA.- Fran Adams自2026年4月起担任Research Alliance Corporation IV的首席财务官。Adams先生目前是van den Boom and Associates的合伙人，拥有超过20年的会计和财务经验。Adams先生在多家私营生命科学公司担任零碎首席财务官以及财务和会计主管。在加入van den Boom and Associates之前，他曾在多家上市公司工作，专注于财务报告和技术会计。Adams先生还曾担任Research Alliance Corporation III自2026年2月成立以来的首席财务官。Adams博士拥有圣地亚哥州立大学会计专业的工商管理学士学位，是一名活跃的加州注册会计师。
- Fran Adams has been Research Alliance Corporation Iv's Chief Financial Officer since April 2026. Mr. Adams is currently a Partner at van den Boom and Associates with over 20 years of accounting and finance experience. Mr. Adams serves as the fractional chief financial officer and head of finance and accounting at various private life sciences companies. Prior to joining van den Boom and Associates worked at multiple public companies focusing on financial reporting and technical accounting. Mr. Adams has also served as Chief Financial Officer of Research Alliance Corporation III since its inception in February 2026. Dr Adams holds a bachelor's degree in Business Administration with emphasis in accounting from San Diego State University and is an active California CPA.
- Ali Jackson
- 暂无中文简介
Ali Jackson has served as Frazier Life Sciences Acquisition Corp. Ii's General Counsel since Frazier Life Sciences Acquisition Corp. Ii's inception in August 2026. Ms. Jackson joined the Fraizer Life Sciences team in 2023 and has served in increasing roles of responsibility within the public funds group of the legal department, most recently as Vice President and Counsel of Public Funds since January 2025. Prior to joining FLS, Ms. Jackson was an associate at Davis Polk & Wardwell LLP from October 2017 to September 2023 where she focused on corporate securities, corporate governance and mergers and acquisitions. Ms. Jackson holds a bachelor's degree in economics from University of California, Santa Barbara and a J.D. from University of Southern California, Gould School of Law. - 暂无中文简介
- Ali Jackson has served as Frazier Life Sciences Acquisition Corp. Ii's General Counsel since Frazier Life Sciences Acquisition Corp. Ii's inception in August 2026. Ms. Jackson joined the Fraizer Life Sciences team in 2023 and has served in increasing roles of responsibility within the public funds group of the legal department, most recently as Vice President and Counsel of Public Funds since January 2025. Prior to joining FLS, Ms. Jackson was an associate at Davis Polk & Wardwell LLP from October 2017 to September 2023 where she focused on corporate securities, corporate governance and mergers and acquisitions. Ms. Jackson holds a bachelor's degree in economics from University of California, Santa Barbara and a J.D. from University of Southern California, Gould School of Law.
- Kevin Li
- 暂无中文简介
Kevin Li has served as Frazier Life Sciences Acquisition Corp. Ii's Chief Business Officer since Frazier Life Sciences Acquisition Corp. Ii's inception in August 2026. Dr. Li joined FLS in 2021 and invests in public and late stage private companies for the FLSPF. He led the fund's investments in Scorpion Therapeutics, Inc. which was acquired by Eli Lilly and Company in 2025, 35Pharma Inc. which was acquired by GSK in 2026, and Angitia Biopharmaceuticals Limited, where he currently serves on the board of directors. Dr. Li was previously a resident physician in Internal Medicine at Stanford and a consultant at McKinsey & Company, where he focused on corporate strategy, growth, and M&A in the hospital services and pharmaceutical industries. Dr. Li received his M.D. from Stanford University and his B.S. from Yale University, where he graduated summa cum laude in Molecular Biophysics and Biochemistry. - 暂无中文简介
- Kevin Li has served as Frazier Life Sciences Acquisition Corp. Ii's Chief Business Officer since Frazier Life Sciences Acquisition Corp. Ii's inception in August 2026. Dr. Li joined FLS in 2021 and invests in public and late stage private companies for the FLSPF. He led the fund's investments in Scorpion Therapeutics, Inc. which was acquired by Eli Lilly and Company in 2025, 35Pharma Inc. which was acquired by GSK in 2026, and Angitia Biopharmaceuticals Limited, where he currently serves on the board of directors. Dr. Li was previously a resident physician in Internal Medicine at Stanford and a consultant at McKinsey & Company, where he focused on corporate strategy, growth, and M&A in the hospital services and pharmaceutical industries. Dr. Li received his M.D. from Stanford University and his B.S. from Yale University, where he graduated summa cum laude in Molecular Biophysics and Biochemistry.
- Albert Cha
自2016年Carbylan Therapeutics，Inc.交易完成以来，Albert Cha一直担任我们的董事会成员。Cha博士从2007年11月开始担任Carbylan董事会成员。他于2000年9月加入Vivo Capital公司（梦百合投资公司），在那里他曾担任多种职务。Cha博士目前担任Ascendis PharmaA/s和几家私营生物技术和医疗设备公司的董事会成员。在过去的五年中，他还担任过生物医药控股有限公司、AclarisTherapeutics，Inc.、SierraOncology，Inc.（前身为Pronai Therapeutics，Inc.和AirxPanders，Inc.）的董事会成员。Cha博士获得斯坦福大学（Stanford University）的B.S.和M.S.以及加州大学洛杉矶分校（University of California at Los Angeles）的M.D.和博士学位。
Albert Cha has served as a member of board of directors since November 2014 and as the Chairman of board of directors since May 2021. Dr. Cha is a Managing Partner with Frazier Life Sciences. He previoly was a managing partner at Vivo Capital LLC, a healthcare investment firm, where he has served in vario positions, most recently as a managing partner. Dr. Cha previoly served as a member of the board of directors of KalVista Pharmaceuticals, Inc., Aclaris Therapeutics, a publicly traded dermatology company, Sierra Oncology, Inc., a publicly traded oncology company, Biohaven Pharmaceutical Holding Company Ltd, a publicly traded clinical stage biopharmaceutical company targeting neurological diseases and Menlo Therapeutics, Inc., a publicly traded late stage biopharmaceutical company focused on the treatment of prurit. Dr. Cha holds a B.S. and an M.S. from Stanford University and an M.D. and a Ph.D. from the University of California at Los Angeles.- 自2016年Carbylan Therapeutics，Inc.交易完成以来，Albert Cha一直担任我们的董事会成员。Cha博士从2007年11月开始担任Carbylan董事会成员。他于2000年9月加入Vivo Capital公司（梦百合投资公司），在那里他曾担任多种职务。Cha博士目前担任Ascendis PharmaA/s和几家私营生物技术和医疗设备公司的董事会成员。在过去的五年中，他还担任过生物医药控股有限公司、AclarisTherapeutics，Inc.、SierraOncology，Inc.（前身为Pronai Therapeutics，Inc.和AirxPanders，Inc.）的董事会成员。Cha博士获得斯坦福大学（Stanford University）的B.S.和M.S.以及加州大学洛杉矶分校（University of California at Los Angeles）的M.D.和博士学位。
- Albert Cha has served as a member of board of directors since November 2014 and as the Chairman of board of directors since May 2021. Dr. Cha is a Managing Partner with Frazier Life Sciences. He previoly was a managing partner at Vivo Capital LLC, a healthcare investment firm, where he has served in vario positions, most recently as a managing partner. Dr. Cha previoly served as a member of the board of directors of KalVista Pharmaceuticals, Inc., Aclaris Therapeutics, a publicly traded dermatology company, Sierra Oncology, Inc., a publicly traded oncology company, Biohaven Pharmaceutical Holding Company Ltd, a publicly traded clinical stage biopharmaceutical company targeting neurological diseases and Menlo Therapeutics, Inc., a publicly traded late stage biopharmaceutical company focused on the treatment of prurit. Dr. Cha holds a B.S. and an M.S. from Stanford University and an M.D. and a Ph.D. from the University of California at Los Angeles.